Palatin Technologies Overview
- Year Founded
-
1986
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
PTN
- Share Price
-
$4.56
- (As of Friday Closing)
Palatin Technologies General Information
Description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.
Contact Information
Website
www.palatin.comCorporate Office
- 301 Carnegie Center Drive
- Suite 304
- Princeton, NJ 08540
- United States
Corporate Office
- 301 Carnegie Center Drive
- Suite 304
- Princeton, NJ 08540
- United States
Palatin Technologies Timeline
Palatin Technologies Stock Performance
As of 20-Nov-2026, Palatin Technologies’s stock price is $4.56. Its current market cap is $8.16M with 1.78M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.56 | $5.00 | $4.51 - $31.00 | $8.16M | 1.78M | 71K | -$5.85 |
Palatin Technologies Financials Summary
As of 30-Sep-2026, Palatin Technologies has a trailing 12-month revenue of $4.7M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 8,529 | 9,326 | 4,249 | 22,159 |
| Revenue | 4,699 | 13,185 | 0 | 4,490 |
| EBITDA | (18,041) | (8,308) | (17,033) | (29,380) |
| Net Income | (18,113) | (8,378) | (17,307) | (29,736) |
| Total Assets | 4,718 | 8,524 | 3,267 | 10,742 |
| Total Debt | 160 | 224 | 164 | 590 |
Palatin Technologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Palatin Technologies Comparisons
Industry
Financing
Details
Palatin Technologies Competitors (17)
One of Palatin Technologies’s 17 competitors is AIM ImmunoTech, a Corporation company based in Ocala, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AIM ImmunoTech | Corporation | Ocala, FL | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Kala Bio | Formerly VC-backed | Arlington, MA | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Paratek Pharmaceuticals | Private Equity-Backed | King of Prussia, PA |
Palatin Technologies Patents
Palatin Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3166466-A1 | Diamine-linked receptor-specific cyclic peptides | Pending | 03-Feb-2020 | ||
| WO-2021158463-A1 | Diamine-linked receptor-specific cyclic peptides | Inactive | 03-Feb-2020 | ||
| AU-2021217939-A1 | Reverse amide-linked melanocortin receptor-specific cyclic peptides | Pending | 03-Feb-2020 | ||
| CA-3166448-A1 | Reverse amide-linked melanocortin receptor-specific cyclic peptides | Pending | 03-Feb-2020 | ||
| EP-4100042-A1 | Reverse amide-linked melanocortin receptor-specific cyclic peptides | Pending | 03-Feb-2020 | C07K7/64 |
Palatin Technologies Signals
Palatin Technologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Palatin Technologies ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Palatin Technologies FAQs
-
When was Palatin Technologies founded?
Palatin Technologies was founded in 1986.
-
Where is Palatin Technologies headquartered?
Palatin Technologies is headquartered in Princeton, NJ.
-
What is the size of Palatin Technologies?
Palatin Technologies has 25 total employees.
-
What industry is Palatin Technologies in?
Palatin Technologies’s primary industry is Pharmaceuticals.
-
Is Palatin Technologies a private or public company?
Palatin Technologies is a Public company.
-
What is Palatin Technologies’s stock symbol?
The ticker symbol for Palatin Technologies is PTN.
-
What is the current stock price of Palatin Technologies?
As of 20-Nov-2026 the stock price of Palatin Technologies is $4.56.
-
What is the current market cap of Palatin Technologies?
The current market capitalization of Palatin Technologies is $8.16M.
-
What is Palatin Technologies’s current revenue?
The trailing twelve month revenue for Palatin Technologies is $4.7M.
-
Who are Palatin Technologies’s competitors?
AIM ImmunoTech, Aldeyra Therapeutics, Kala Bio, Ardelyx, and Paratek Pharmaceuticals are some of the 17 competitors of Palatin Technologies.
-
What is Palatin Technologies’s annual earnings per share (EPS)?
Palatin Technologies’s EPS for 12 months was -$5.85.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process